A newly identified subtype of Castleman disease will help diagnose and properly treat thousands of patients who have been caught between existing classification systems, marking the first major ...

The analyst highlights that Lilly’s drugs, Mounjaro and Zepbound, will likely keep gaining U.S. market share from Novo ...

The drugmaker reported disappointing data from a mid-stage trial for its weight-loss pill monlunabant last year, followed by results for a separate experimental shot called CagriSema that missed ...

Products are independently selected by our editors. We may earn an affiliate commission from links. A Pierce & Ward room has an unmistakable presence. Thoughtfully layered patterns, plush textures ...

Also, Cagrisema, their drug in Phase 2 development, achieved 22.7% of weight loss in patients part of the 68-week REDEFINE 1 study. In REDEFINE 2, patients lost 15.1% of weight in the same time ...

Headline results from a REDEFINE-2 late-stage trial released earlier this month showed that CagriSema helped obese or overweight adult patients with type 2 diabetes lose 15.7% of their weight ...

The company is developing CagriSema as a weight management medicine. In December, Novo Nordisk reported that CagriSema helped patients lose, on average, 22.7% of their body weight in a phase 3 study.

According to the company, the CagriSema combination therapy has shown 22.7% weight loss in the REDEFINE 1 trial, which outperformed semaglutide alone (16.1%) and placebo (2.3%). Now, a new Phase ...